SF3A3 and colorectal carcinoma: In addition, high-throughput virtual screening predicted a close binding of the active site of PEITC to SF3A3 and the subsequent experimental findings demonstrated that PEITC may exert its effect through inhibiting the expression of SF3A3. PEITC has been used in clinical trials studying the prevention and treatment of leukemia34 and lung cancer35, but has not yet been tested and applied in CRC treatment.